What are the major opportunities in the HER2-Positive Breast Cancer market? What are the strategies for the HER2-Positive Breast Cancer market?

For detailed insights on the major opportunities and strategies in the HER2-Positive Breast Cancer market, Read More

How does the HER2-Positive Breast Cancer market relate to the overall economy and other similar markets?

For detailed insights on HER2-Positive Breast Cancer's relation to the overall economy and other similar markets, Read More

What are the key dynamics influencing the HER2-Positive Breast Cancer market growth? SWOT analysis of the HER2-Positive Breast Cancer market.

For detailed insights on the key dynamics influencing the HER2-Positive Breast Cancer market growth and SWOT analysis of the HER2-Positive Breast Cancer industry, Read More

Global HER2 Positive Breast Cancer Market Report 2025

Item added to cart!

Report Price : $4490.00

Pages :

Format : PDF

Published : December 2025

Delivery Time : 2-3 Business Days

Purchase This Report Download Sample PDF

Purchase This Report

HER2-Positive Breast Cancer Global Market Report 2025

Name: HER2-Positive Breast Cancer Global Market Report 2025
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

By Treatment Type (Targeted Therapy, Chemotherapy, Endocrine Therapy, Immunotherapy, Other Treatment Types), By Route Of Administration (Parenteral, Oral, Other Route Of Administrations), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By End User (Hospitals, Homecare, Specialty Clinics, Other End User) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

HER2-Positive Breast Cancer Market Overview

• HER2-Positive Breast Cancer market size has reached to $10.21 billion in 2024

• Expected to grow to $14.3 billion in 2029 at a compound annual growth rate (CAGR) of 6.9%

• Growth Driver: Impact Of Immunotherapy Adoption On The HER2-Positive Breast Cancer Market

• Market Trend: Innovative Therapies In The HER2-Positive Breast Cancer Market

• North America was the largest region in 2024 and Asia-Pacific is the fastest growing region.

What Is Covered Under HER2-Positive Breast Cancer Market?

HER2-positive breast cancer refers to a type of breast cancer characterized by the overexpression of the human epidermal growth factor receptor 2 (HER2) protein. This protein promotes the growth of cancer cells and is found in approximately 15-20% of breast cancers. HER2-positive breast cancer is generally more aggressive than HER2-negative forms but is treatable with targeted therapies that inhibit HER2 activity.

The main types of treatments for HER2-positive breast cancer are targeted therapy, chemotherapy, endocrine therapy, immunotherapy, and other treatment types. Targeted therapy is a cancer treatment that precisely attacks specific molecules, such as proteins or genes driving cancer growth, while sparing normal cells. These drugs are administered through various routes, including parenteral, oral, and other route of administrations. It is distributed through various channels such as hospital pharmacy, retail pharmacy, and online pharmacy and is used by various end users including hospitals, homecare, specialty clinics, and others.

HER2-Positive Breast Cancer Market Size and growth rate 2025 to 2029: Graph

What Is The HER2-Positive Breast Cancer Market Size 2025 And Growth Rate?

The HER2-positive breast cancer market size has grown strongly in recent years. It will grow from $10.21 billion in 2024 to $10.93 billion in 2025 at a compound annual growth rate (CAGR) of 7.0%. The growth in the historic period can be attributed to increasing early detection and diagnosis, rising awareness of HER2-positive subtypes, growing investments in research and development, rising adoption of precision medicine, and growing focus on improving patient outcomes.

What Is The HER2-Positive Breast Cancer Market Growth Forecast?

The HER2-positive breast cancer market size is expected to see strong growth in the next few years. It will grow to $14.3 billion in 2029 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to rising demand for liquid biopsy for non-invasive monitoring, rising adoption of combination treatments, growing focus on immunotherapies and novel drug formulations, increasing use of liquid biopsy techniques for non-invasive monitoring, and increasing number of specialized cancer treatment centers. Major trends in the forecast period include advancements in targeted therapies, novel formulations, innovations in immunotherapy approaches, the development of novel HER2-targeted therapies, and advancements in biomarkers for better patient stratification.

The forecast of 6.9% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may disrupt U.S. cancer care by increasing costs for trastuzumab biosimilars and pertuzumab imported from South Korea and Switzerland, potentially leading to treatment rationing and higher out-of-pocket costs for patients. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Book your 30 minutes free consultation with our research experts

What’s The Trade War Impact On Healthcare Services Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

How Is The HER2-Positive Breast Cancer Market Segmented?

1) By Treatment Type: Targeted Therapy, Chemotherapy, Endocrine Therapy, Immunotherapy, Other Treatment Types

2) By Route Of Administration: Parenteral, Oral, Other Route Of Administrations

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End User

Subsegments:

1) By Targeted Therapy: HER2 Inhibitors (Trastuzumab, Pertuzumab), Tyrosine Kinase Inhibitors (TKIs), Antibody-Drug Conjugates (ADC), Small Molecule Inhibitors

2) By Chemotherapy: Anthracycline-based Chemotherapy, Taxane-based Chemotherapy, Platinum-based Chemotherapy, Combination Chemotherapy Regimens

3) By Endocrine Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Estrogen Receptor Antagonists, Estrogen Deprivation Therapy

4) By Immunotherapy: Immune Checkpoint Inhibitors (PD-1/PD-L1 Inhibitors), Monoclonal Antibodies for Immune Modulation, Cancer Vaccines

5) By Other Treatment Types: Radiation Therapy, Stem Cell Therapy, Hyperthermia Treatment, Gene Therapy, Surgical Interventions (Mastectomy, Breast Conserving Surgery)

What Is Driving The HER2-Positive Breast Cancer Market? Impact Of Immunotherapy Adoption On The HER2-Positive Breast Cancer Market

The strong adoption of immunotherapy is expected to propel the growth of the HER2-positive breast cancer market going forward. Immunotherapy refers to a medical treatment that enhances or modifies the immune system's natural ability to fight diseases, such as cancer, infections, and autoimmune disorders. The adoption of immunotherapy is attributed to its capability to enhance the immune system's ability to identify and eliminate cancer cells, providing better efficacy and fewer side effects than conventional treatments. Immunotherapy aids HER2-positive breast cancer by enhancing the body's immune system to recognize and attack HER2-overexpressing cancer cells, improving treatment outcomes and reducing the risk of recurrence. For instance, in July 2023, according to the American Association for Cancer Research, a US-based organization, in 2023, the FDA has approved 11 immune checkpoint inhibitors (ICIs), with at least one ICI authorized for the treatment of 20 different cancer types and for any solid tumor exhibiting specific molecular characteristics. Therefore, the strong adoption of immunotherapy is driving the growth of the HER2-positive breast cancer industry.

Who Are The Major Players In The Global HER2-Positive Breast Cancer Market?

Major companies operating in the HER2-positive breast cancer market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Novartis International AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim GmbH, Daiichi Sankyo Co. Ltd., Incyte Corporation, BioNTech SE, MacroGenics Inc., CStone Pharmaceuticals Co. Ltd., Sorrento Therapeutics Inc., Syndax Pharmaceuticals Inc., Fate Therapeutics Inc., Ambrx Biopharma Inc.

What Are The Key Trends Of The Global HER2-Positive Breast Cancer Market? Innovative Therapies In The HER2-Positive Breast Cancer Market

Major companies operating in the HER2-positive breast cancer market are focused on developing innovative therapies, such as her2-directed antibody-drug conjugates (ADCs), to streamline and enhance the treatment process for patients. HER2-directed antibody-drug conjugates (ADCs) are targeted cancer therapies that link an antibody specific to HER2 with a cytotoxic drug, delivering the drug directly to HER2-positive cancer cells for more effective treatment. For instance, in January 2024, AstraZeneca India Pharma Ltd., an India-based biopharmaceutical company, launched Trastuzumab deruxtecan. This innovative therapy was developed through a collaboration between AstraZeneca and Daiichi Sankyo. Trastuzumab deruxtecan is a HER2-directed antibody-drug conjugate (ADC), which delivers a cytotoxic drug directly to HER2-positive cancer cells, offering a more targeted and effective treatment for patients.

Need data on a specific region in this market?

Request Regional Data

What Are Latest Mergers And Acquisitions In The HER2-Positive Breast Cancer Market? Roche Acquires Rights To Zion Pharma's ZN-A-1041 For Brain Metastases Treatment In HER2-Positive Breast Cancer

In May 2023, Roche Holding AG, a Switzerland-based pharmaceutical company, acquired rights to Zion’s lead program, ZN-A-1041, for an undisclosed amount. The acquisition aims to advance the development and commercialization of Zion Pharma's ZN-A-1041, a blood-brain-barrier-penetrant HER2 inhibitor, for treating brain metastases in HER2-positive breast cancer patients. Zion Pharma Limited, a China-based biotechnology company that specializes in providing drugs to treat HER2-positive breast cancer.

What Is The Regional Outlook For The Global HER2-Positive Breast Cancer Market?

North America was the largest region in the HER2- positive breast cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the HER2-Positive Breast Cancer Market?

The HER2-positive breast cancer market consists of sales of small molecule inhibitors, antibody-drug conjugates, and monoclonal antibodies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the HER2-Positive Breast Cancer Industry?

The her2-positive breast cancer market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the her2-positive breast cancer industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

HER2-Positive Breast Cancer Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2025	$10.93 billion
Revenue Forecast In 2034	$14.3 billion
Growth Rate	CAGR of 6.9% from 2025 to 2034
Base Year For Estimation	2024
Actual Estimates/Historical Data	2019-2024
Forecast Period	2025 - 2029 - 2034
Market Representation	Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered	The HER2-positive breast cancer market covered in this report is segmented – 1) By Treatment Type: Targeted Therapy, Chemotherapy, Endocrine Therapy, Immunotherapy, Other Treatment Types 2) By Route Of Administration: Parenteral, Oral, Other Route Of Administrations 3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy 4) By End User: Hospitals, Homecare, Specialty Clinics, Other End User Subsegments: 1) By Targeted Therapy: HER2 Inhibitors (Trastuzumab, Pertuzumab), Tyrosine Kinase Inhibitors (TKIs), Antibody-Drug Conjugates (ADC), Small Molecule Inhibitors 2) By Chemotherapy: Anthracycline-based Chemotherapy, Taxane-based Chemotherapy, Platinum-based Chemotherapy, Combination Chemotherapy Regimens 3) By Endocrine Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Estrogen Receptor Antagonists, Estrogen Deprivation Therapy 4) By Immunotherapy: Immune Checkpoint Inhibitors (PD-1/PD-L1 Inhibitors), Monoclonal Antibodies for Immune Modulation, Cancer Vaccines 5) By Other Treatment Types: Radiation Therapy, Stem Cell Therapy, Hyperthermia Treatment, Gene Therapy, Surgical Interventions (Mastectomy, Breast Conserving Surgery)
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled	Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Novartis International AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim GmbH, Daiichi Sankyo Co. Ltd., Incyte Corporation, BioNTech SE, MacroGenics Inc., CStone Pharmaceuticals Co. Ltd., Sorrento Therapeutics Inc., Syndax Pharmaceuticals Inc., Fate Therapeutics Inc., Ambrx Biopharma Inc.
Customization Scope	Request for Sample
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

2. HER2-Positive Breast Cancer Market Characteristics

3. HER2-Positive Breast Cancer Market Trends And Strategies

4. HER2-Positive Breast Cancer Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global HER2-Positive Breast Cancer Growth Analysis And Strategic Analysis Framework

5.1. Global HER2-Positive Breast Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global HER2-Positive Breast Cancer Market Growth Rate Analysis

5.4. Global HER2-Positive Breast Cancer Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global HER2-Positive Breast Cancer Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global HER2-Positive Breast Cancer Total Addressable Market (TAM)

6. HER2-Positive Breast Cancer Market Segmentation

6.1. Global HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Targeted Therapy

Chemotherapy

Endocrine Therapy

Immunotherapy

Other Treatment Types

6.2. Global HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Parenteral

Oral

Other Route Of Administrations

6.3. Global HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

6.4. Global HER2-Positive Breast Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospitals

Homecare

Specialty Clinics

Other End User

6.5. Global HER2-Positive Breast Cancer Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

HER2 Inhibitors (Trastuzumab, Pertuzumab)

Tyrosine Kinase Inhibitors (TKIs)

Antibody-Drug Conjugates (ADC)

Small Molecule Inhibitors

6.6. Global HER2-Positive Breast Cancer Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Anthracycline-based Chemotherapy

Taxane-based Chemotherapy

Platinum-based Chemotherapy

Combination Chemotherapy Regimens

6.7. Global HER2-Positive Breast Cancer Market, Sub-Segmentation Of Endocrine Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Selective Estrogen Receptor Modulators (SERMs)

Aromatase Inhibitors

Estrogen Receptor Antagonists

Estrogen Deprivation Therapy

6.8. Global HER2-Positive Breast Cancer Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Immune Checkpoint Inhibitors (PD-1/PD-L1 Inhibitors)

Monoclonal Antibodies for Immune Modulation

Cancer Vaccines

6.9. Global HER2-Positive Breast Cancer Market, Sub-Segmentation Of Other Treatment Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Radiation Therapy

Stem Cell Therapy

Hyperthermia Treatment

Gene Therapy

Surgical Interventions (Mastectomy, Breast Conserving Surgery)

7. HER2-Positive Breast Cancer Market Regional And Country Analysis

7.1. Global HER2-Positive Breast Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global HER2-Positive Breast Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific HER2-Positive Breast Cancer Market

8.1. Asia-Pacific HER2-Positive Breast Cancer Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China HER2-Positive Breast Cancer Market

9.1. China HER2-Positive Breast Cancer Market Overview

9.2. China HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India HER2-Positive Breast Cancer Market

10.1. India HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan HER2-Positive Breast Cancer Market

11.1. Japan HER2-Positive Breast Cancer Market Overview

11.2. Japan HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia HER2-Positive Breast Cancer Market

12.1. Australia HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia HER2-Positive Breast Cancer Market

13.1. Indonesia HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea HER2-Positive Breast Cancer Market

14.1. South Korea HER2-Positive Breast Cancer Market Overview

14.2. South Korea HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe HER2-Positive Breast Cancer Market

15.1. Western Europe HER2-Positive Breast Cancer Market Overview

15.2. Western Europe HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK HER2-Positive Breast Cancer Market

16.1. UK HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany HER2-Positive Breast Cancer Market

17.1. Germany HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France HER2-Positive Breast Cancer Market

18.1. France HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy HER2-Positive Breast Cancer Market

19.1. Italy HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain HER2-Positive Breast Cancer Market

20.1. Spain HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe HER2-Positive Breast Cancer Market

21.1. Eastern Europe HER2-Positive Breast Cancer Market Overview

21.2. Eastern Europe HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia HER2-Positive Breast Cancer Market

22.1. Russia HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America HER2-Positive Breast Cancer Market

23.1. North America HER2-Positive Breast Cancer Market Overview

23.2. North America HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA HER2-Positive Breast Cancer Market

24.1. USA HER2-Positive Breast Cancer Market Overview

24.2. USA HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada HER2-Positive Breast Cancer Market

25.1. Canada HER2-Positive Breast Cancer Market Overview

25.2. Canada HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America HER2-Positive Breast Cancer Market

26.1. South America HER2-Positive Breast Cancer Market Overview

26.2. South America HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil HER2-Positive Breast Cancer Market

27.1. Brazil HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East HER2-Positive Breast Cancer Market

28.1. Middle East HER2-Positive Breast Cancer Market Overview

28.2. Middle East HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa HER2-Positive Breast Cancer Market

29.1. Africa HER2-Positive Breast Cancer Market Overview

29.2. Africa HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. HER2-Positive Breast Cancer Market Competitive Landscape And Company Profiles

30.1. HER2-Positive Breast Cancer Market Competitive Landscape

30.2. HER2-Positive Breast Cancer Market Company Profiles

30.2.1. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. HER2-Positive Breast Cancer Market Other Major And Innovative Companies

31.1. AstraZeneca plc

31.2. Novartis International AG

31.3. GlaxoSmithKline plc

31.4. Eli Lilly and Company

31.5. Amgen Inc.

31.6. Boehringer Ingelheim GmbH

31.7. Daiichi Sankyo Co. Ltd.

31.8. Incyte Corporation

31.9. BioNTech SE

31.10. MacroGenics Inc.

31.11. CStone Pharmaceuticals Co. Ltd.

31.12. Sorrento Therapeutics Inc.

31.13. Syndax Pharmaceuticals Inc.

31.14. Fate Therapeutics Inc.

31.15. Ambrx Biopharma Inc.

32. Global HER2-Positive Breast Cancer Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The HER2-Positive Breast Cancer Market

34. Recent Developments In The HER2-Positive Breast Cancer Market

35. HER2-Positive Breast Cancer Market High Potential Countries, Segments and Strategies

35.1 HER2-Positive Breast Cancer Market In 2029 - Countries Offering Most New Opportunities

35.2 HER2-Positive Breast Cancer Market In 2029 - Segments Offering Most New Opportunities

35.3 HER2-Positive Breast Cancer Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2019-2024, $ Billion

Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Table 3: Global HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 4: Global HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 5: Global HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 6: Global HER2-Positive Breast Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 7: Global HER2-Positive Breast Cancer Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 8: Global HER2-Positive Breast Cancer Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 9: Global HER2-Positive Breast Cancer Market, Sub-Segmentation Of Endocrine Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 10: Global HER2-Positive Breast Cancer Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 11: Global HER2-Positive Breast Cancer Market, Sub-Segmentation Of Other Treatment Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 12: Global HER2-Positive Breast Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 13: Global HER2-Positive Breast Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 14: Asia-Pacific, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 15: Asia-Pacific, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 16: Asia-Pacific, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 17: China, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 18: China, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 19: China, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 20: India, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 21: India, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 22: India, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 23: Japan, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 24: Japan, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 25: Japan, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 26: Australia, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 27: Australia, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 28: Australia, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 29: Indonesia, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 30: Indonesia, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 31: Indonesia, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 32: South Korea, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 33: South Korea, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 34: South Korea, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 35: Western Europe, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 36: Western Europe, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 37: Western Europe, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 38: UK, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 39: UK, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 40: UK, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 41: Germany, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 42: Germany, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 43: Germany, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 44: France, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 45: France, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 46: France, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 47: Italy, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 48: Italy, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 49: Italy, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 50: Spain, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 51: Spain, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 52: Spain, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 53: Eastern Europe, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 54: Eastern Europe, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 55: Eastern Europe, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 56: Russia, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 57: Russia, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 58: Russia, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 59: North America, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 60: North America, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 61: North America, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 62: USA, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 63: USA, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 64: USA, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 65: Canada, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 66: Canada, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 67: Canada, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 68: South America, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 69: South America, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 70: South America, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 71: Brazil, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 72: Brazil, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 73: Brazil, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 74: Middle East, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 75: Middle East, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 76: Middle East, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 77: Africa, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 78: Africa, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 79: Africa, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 80: Johnson & Johnson Services Inc. Financial Performance

Table 81: F. Hoffmann-La Roche AG Financial Performance

Table 82: Merck & Co. Inc. Financial Performance

Table 83: Bayer AG Financial Performance

Table 84: Sanofi S.A. Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2019-2024, $ Billion

Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Figure 3: Global HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 4: Global HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 5: Global HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 6: Global HER2-Positive Breast Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 7: Global HER2-Positive Breast Cancer Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 8: Global HER2-Positive Breast Cancer Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 9: Global HER2-Positive Breast Cancer Market, Sub-Segmentation Of Endocrine Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 10: Global HER2-Positive Breast Cancer Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 11: Global HER2-Positive Breast Cancer Market, Sub-Segmentation Of Other Treatment Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 12: Global HER2-Positive Breast Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 13: Global HER2-Positive Breast Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 14: Asia-Pacific, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 15: Asia-Pacific, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 16: Asia-Pacific, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 17: China, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 18: China, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 19: China, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 20: India, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 21: India, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 22: India, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 23: Japan, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 24: Japan, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 25: Japan, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 26: Australia, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 27: Australia, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 28: Australia, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 29: Indonesia, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 30: Indonesia, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 31: Indonesia, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 32: South Korea, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 33: South Korea, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 34: South Korea, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 35: Western Europe, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 36: Western Europe, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 37: Western Europe, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 38: UK, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 39: UK, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 40: UK, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 41: Germany, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 42: Germany, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 43: Germany, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 44: France, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 45: France, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 46: France, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 47: Italy, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 48: Italy, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 49: Italy, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 50: Spain, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 51: Spain, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 52: Spain, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 53: Eastern Europe, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 54: Eastern Europe, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 55: Eastern Europe, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 56: Russia, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 57: Russia, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 58: Russia, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 59: North America, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 60: North America, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 61: North America, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 62: USA, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 63: USA, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 64: USA, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 65: Canada, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 66: Canada, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 67: Canada, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 68: South America, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 69: South America, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 70: South America, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 71: Brazil, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 72: Brazil, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 73: Brazil, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 74: Middle East, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 75: Middle East, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 76: Middle East, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 77: Africa, HER2-Positive Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 78: Africa, HER2-Positive Breast Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 79: Africa, HER2-Positive Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 80: Johnson & Johnson Services Inc. Financial Performance

Figure 81: F. Hoffmann-La Roche AG Financial Performance

Figure 82: Merck & Co. Inc. Financial Performance

Figure 83: Bayer AG Financial Performance

Figure 84: Sanofi S.A. Financial Performance

From Insight to Impact: Strategic Growth Mapping in the HER2-Positive Breast Cancer Market

Hospital And Nursing Home Probiotics Market Overview 2025: Competitive Shifts, Forecast Models, and Emerging Opportunities

Next-Gen Implantable Cardioverter Defibrillators (ICDs) : Market Forecast, Transformation, and Long-Term Trajectories

Indwelling Catheters Growth Trajectory: Key Forecasts and Strategic Insights

A strategic 2025 report providing key insights, trends and forecasts for the global live attenuated polio vaccine market between 2025–2034.

A 2025 forecast report outlining growth projections, key trends and regulatory landscape of the medicated shampoo market through 2029.

Explore strategic insights and forecasts in the global virtual nutrition coach app market, offering competitive benchmarking and market growth trends.

Explore the latest trends, growth insights, and forecasts in the Key Trend Shaping The Ophthalmology Medical Service Market.

Breast Cancer Diagnostics Global Market Report 2025 – By Type (Imaging, Biopsy, Genomic Tests, Blood Tests, Other Types), By Technology (Fluorescent In Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), ...

Breast Cancer Drugs Global Market Report 2025 – By Type (Metastatic Breast Cancer, Triple Negative Breast Cancer, Others (Ductal Carcinoma Insitu, Invasive Ductal Carcinoma, Inflammatory Breast Cancer, Breast Cancer Duri...

Metastatic HR+/HER2- Breast Cancer Global Market Report 2025 – By Drugs (Paclitaxel, Tamoxifen, Vinblastine, Raloxifene, Docetaxel, Other Drugs), By Treatment (Radiation Therapy, Vitamin Therapy, Macrobiotic Diets, Homeo...

Hereditary Breast and Ovarian Cancer Syndrome Treatment Global Market Report 2025 – By Treatment (Hormonal Therapy, Chemoprevention, Genetic Counselling, Medication, Other Treatments), By Diagnosis (Genetic Testing, Magn...

Metastatic Breast Cancer Treatment Global Market Report 2025 – By Therapy Type (Chemotherapy, Radiation Therapy, Biologic Targeted Therapy, Breast Surgery, Hormone Therapy), By Molecule Type (Monoclonal Antibody, Peptide...

Cancer Biomarker Global Market Report 2025 – By Biomarkers Type (Protein Biomarkers, Genetic Biomarkers, Other Cancer Biomarkers), By Profiling Technologies (Omics Technologies, Imaging Technologies, Immunoassay, Bioinfo...

Next-Generation Gynecological Cancer Diagnostics Global Market Report 2025 – By Cancer Type (Cervical Cancer, Ovarian Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer), By Function (Therapeutic Monitoring, Companion...

Frequently Asked Questions

What is the definition of the HER2-Positive Breast Cancer market?

How will the HER2-Positive Breast Cancer market drivers and restraints affect the market dynamics? What forces will shape the HER2-Positive Breast Cancer industry going forward?

The market major growth driver - Impact Of Immunotherapy Adoption On The HER2-Positive Breast Cancer Market. For further insights on this market, request a sample here

What is the forecast market size or the forecast market value of the HER2-Positive Breast Cancer market?

The her2-positive breast cancer market size has grown strongly in recent years. It will grow from $10.21 billion in 2024 to $10.93 billion in 2025 at a compound annual growth rate (CAGR) of 7.0%. The growth in the historic period can be attributed to increasing early detection and diagnosis, rising awareness of HER2-positive subtypes, growing investments in research and development, rising adoption of precision medicine, and growing focus on improving patient outcomes. The her2-positive breast cancer market size is expected to see strong growth in the next few years. It will grow to " $14.3 billion in 2029 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to rising demand for liquid biopsy for non-invasive monitoring, rising adoption of combination treatments, growing focus on immunotherapies and novel drug formulations, increasing use of liquid biopsy techniques for non-invasive monitoring, and increasing number of specialized cancer treatment centers. Major trends in the forecast period include advancements in targeted therapies, novel formulations, innovations in immunotherapy approaches, the development of novel HER2-targeted therapies, and advancements in biomarkers for better patient stratification. For further insights on this market, request a sample here

How is the HER2-Positive Breast Cancer market segmented?

The her2-positive breast cancermarket covered in this report is segmented –
1) By Treatment Type: Targeted Therapy; Chemotherapy; Endocrine Therapy; Immunotherapy; Other Treatment Types
2) By Route Of Administration: Parenteral; Oral; Other Route Of Administrations
3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
4) By End User: Hospitals; Homecare; Specialty Clinics; Other End User Subsegments:
1) By Targeted Therapy: HER2 Inhibitors (Trastuzumab, Pertuzumab); Tyrosine Kinase Inhibitors (TKIs); Antibody-Drug Conjugates (ADC); Small Molecule Inhibitors
2) By Chemotherapy: Anthracycline-based Chemotherapy; Taxane-based Chemotherapy; Platinum-based Chemotherapy; Combination Chemotherapy Regimens
3) By Endocrine Therapy: Selective Estrogen Receptor Modulators (SERMs); Aromatase Inhibitors; Estrogen Receptor Antagonists; Estrogen Deprivation Therapy
4) By Immunotherapy: Immune Checkpoint Inhibitors (PD-1/PD-L1 Inhibitors); Monoclonal Antibodies for Immune Modulation; Cancer Vaccines
5) By Other Treatment Types: Radiation Therapy; Stem Cell Therapy; Hyperthermia Treatment; Gene Therapy; Surgical Interventions (Mastectomy, Breast Conserving Surgery) For further insights on this market, request a sample here

Which region has the largest share of the HER2-Positive Breast Cancer market? What are the other regions covered in the report?

North America was the largest region in the HER2- positive breast cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the HER2-positive breast cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on this market, request a sample here.

Who are the major players in the HER2-Positive Breast Cancer market?

What are the key trends in the HER2-Positive Breast Cancer market?

Major trends in this market include Innovative Therapies In The HER2-Positive Breast Cancer Market. For further insights on this market, request a sample here.